The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)
Condition(s):Metastatic Colorectal CancerLast Updated:August 27, 2021Unknown status
Hide Studies Not Open or Pending
Condition(s):Metastatic Colorectal CancerLast Updated:August 27, 2021Unknown status
Condition(s):OncologyLast Updated:July 12, 2019Completed
Condition(s):Lung CancerLast Updated:August 24, 2023Recruiting
Condition(s):Non-small Cell Lung CancerLast Updated:July 2, 2020Unknown status
Condition(s):Solid Tumor; Oligometastases; Soft Tissue DiseaseLast Updated:April 28, 2022Active, not recruiting
Condition(s):Cardiac Arrhythmia; Cardiac; Ventricular TachyarrhythmiasLast Updated:February 13, 2024Withdrawn
Condition(s):Pancreatic Cancer Non-resectableLast Updated:March 3, 2022Recruiting
Condition(s):Non-Small Cell Lung CancerLast Updated:February 15, 2024Recruiting
Condition(s):Lung Cancer MetastaticLast Updated:December 12, 2023Recruiting
Condition(s):Non-small Cell Lung CancersLast Updated:February 7, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.